Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s research ONE BioHub provides Scott...
AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum The...
GenomOncology announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain canc...
Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...
The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets...
SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collab...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal cong...
-Aceso Interactive, Inc., a leading provider of patient engagement and healthcare communication technology, is pleased to announce a strategic partnershi...
Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic pla...
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter refer...
Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously rece...
Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health ...
Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanis...
siRNA candidate EMP-012 in phase I for treatment of COPD EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose int...
© 2026 Biopharma Boardroom. All Rights Reserved.
